Multiple Dose Study of UCB4940 in Subjects With Psoriatic Arthritis
Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
A study of UCB4940 in subjects with psoriatic arthritis to evaluate the safety and body
distribution of UCB4940 in those patients. Neither the patient nor the doctor will know the
treatment group.
Phase:
Phase 1
Details
Lead Sponsor:
UCB Celltech
Collaborators:
ARENSIA, Moldova Comac Medical COMAC, Bulgaria MAC Clinical Research MAC Clinical Research, United Kingdom Parexel